Abstract

  The pandemic flare-up of coronavirus disease 2019 (COVID-19) is quickly spreading everywhere throughout the world. Reports from China indicated that about 20% of patients created severe disease, bringing about a casualty of 4%. In the previous two months, we clinical immunologists took an interest in multi-rounds of MDT (multidiscipline group) conversation on the counter aggravation the executives of basic COVID-19 patients, with our partners dispatched from Chinese driving PUMC Hospital to Wuhan to concede and treat the most serious patients. Here, from the point of view of clinical immunologists, we will examine the clinical and immunological attributes of severe patients, and sum up the current proof and offer our involvement with hostile to anti-inflammation treatment, including glucocorticoids, IL-6 adversary, JAK inhibitors and chloroquine/hydroxychloroquine, of patients with extreme COVID-19 that may have an impeded safe framework.

Keywords: Coronavirus Disease 2019 (COVID-19); Cytokine Storm; Anti-inflammation Treatment

References

1. R Channappanavar and S Perlman. “Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology”. Seminars in Immunopathology 39 (2017): 529-539.
2. BG Chousterman., et al. “Cytokine storm and sepsis disease pathogenesis”. Seminars in Immunopathology 39 (2017): 517-528.
3. C Huang., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
4. P Conti., et al. “Induction of pro inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies”. Journal of Biological Regulators and Homeostatic Agents 34 (2020): 327-331.
5. F Zhou., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet (2020).
6. Q Ruan., et al. “Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China”. Intensive Care Medicine (2020).
7. N Chen., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 395 (2020): 507-513.
8. C Wu., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease2019 pneumonia in Wuhan, China”. JAMA International Medicine (2020).
9. S Wan., et al. “Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)”. medRxiv (2020).
10. Z Xu., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. Lancet Respiratory Medicine (2020).
11. HK Siddiqi and MR Mehra. “COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal”. Journal of Heart Lung Transplantation5 (2020): 405-407.
12. National Health Commission of the People's Republic of China. The Diagnosis and Treatment Plan for 2019-nCoV (The Seventh Trial Edition).
13. C Qin., et al. “Dysregulation of immune response in patients with COVID-19 in Wuhan, China”. Clinical Infection Disease (2020).
14. XH Yao., et al. “A pathological report of three COVID-19 cases by minimally invasive autopsies”. Chinese Journal of Pathology 49 (2020): E009.
15. X Guo and P Thomas. “New fronts emerge in the influenza cytokine storm”. Seminars in Immunopathology 39 (2017): 541-550.
16. A Shimabukuro-Vornhagen., et al. “Cytokine release syndrome”. Journal of Immunotherapy Cancer 6 (2018): 56.
17. C Chen., et al. “Advances in the research of cytokine storm mechanism induced by Corona virus disease 2019 and the corresponding immunotherapies”. Chinese Journal of Burns 36 (2020): E005.
18. TW Auyeung., et al. “The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study”. International Journal of Information Security 51 (2005): 98-102.
19. JC Ho., et al. “High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome”. American Journal of Respiratory and Critical Care Medicine 168 (2003): 1449-1456.
20. LY Yam., et al. “Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong”. International Journal of Information Security 54 (2007): 28-39.
21. RC Chen., et al. “Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience”. Chest 129 (2006): 1441-1452.
22. A Rhodes., et al. “Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016”. Intensive Care Medicine 43 (2017): 304-377.
23. P Sun., et al. “Understanding of COVID-19 based on current evidence”. Journal of Medical Virology (2020).
24. KW Chan., et al. “COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease”. The American Journal of Chinese Medicine (2020): 1-26.
25. N Chen., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 395 (2020): 507-513.
26. D Wang., et al. “Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China”. JAMA (2020).
27. CD Russell., et al. “Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury”. Lancet 395 (2020): 473-475.
28. World Health Organization, Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected.
29. P Richardson., et al. “Baricitinib as potential treatment for 2019-nCoV acute respiratory disease”. Lancet 395 (2020): e30-e31.
30. J Lajoie., et al. “Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention”. AIDS Research Therapy 14 (2017): 46.
31. A Kumar., et al. “Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease”. ACS Omega 3 (2018): 18132-18141.
32. LF Wang., et al. “Hydroxychloroquine inhibited dengue virus is associated with host defense machinery”. Journal of Interferon and Cytokine Research 35 (2015): 143-156.
33. H Akpovwa. “Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity”. Cell Biochemistry Function 34 (2016): 191-196.
34. DL Barnard., et al. “Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice”. Antiviral Chemistry and Chemotherapy 17 (2006): 275-284.
35. MJ Vincent., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 2 (2005): 69.
36. VB Randolph., et al. “Acidotropic amines inhibit proteolytic processing of flavivirus prM protein”. Virology2 (1990): 450-458.
37. M Wang., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research 30 (2020): 269-271.
38. Q Zhang., et al. “Clinical trial analysis of 2019-nCoV therapy registered in China”. Journal of Medical Virology (2020).
39. L Dong., et al. “Discovering drugs to treat coronavirus disease 2019 (COVID-19)”. Drug Discovery Therapy 14 (2020): 58-60.

Citation

Citation: Anirban Adhikary., et al. “A Review of Anti-Inflammatory Drugs Use in the Treatment of People Infected by Coronavirus Disease 2019 (COVID-19)". Acta Scientific Microbiology 3.11 (2020): 28-34.

Copyright

Copyright: © 2020 Anirban Adhikary., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.